AC
ACAD.US ACADIA Pharmaceuticals Inc
- Market cap
- USD 3.14B
- P/E
- 8.6x
- P/B
- 2.29x
- ROE
- 8.5%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is ACAD.US undervalued?
Graham numberACAD.US trades 6.7% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ACADIA Pharmaceuticals Inc fundamental analysis
No fundamental analysis for ACADIA Pharmaceuticals Inc yet.
ACADIA Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ACADIA Pharmaceuticals Inc
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the sy…
Full company profileACADIA Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ACADIA Pharmaceuticals Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 17.3M | 125M | 224M | 339M | 442M | 484M | 517M | 726M | 958M | 1.07B | 1.22B |
| Gross Profit | 12.9M | 112M | 205M | 319M | 421M | 465M | 507M | 681M | 876M | 983M | 1.11B |
| Operating Income | -273M | -292M | -247M | -247M | -287M | -170M | -224M | -73.4M | 231M | 105M | 140M |
| EBITDA | -271M | -290M | -244M | -244M | -284M | -167M | -222M | -45.5M | 100M | 151M | 160M |
| Net Income | -271M | -289M | -245M | -235M | -282M | -168M | -216M | -61.3M | 226M | 391M | 118M |
| EPS | -2.34 | -2.36 | -1.94 | -1.60 | -1.79 | -1.05 | -1.34 | -0.37 | 1.36 | 2.28 | 0.67 |
| Balance Sheet | |||||||||||
| Total Assets | 561M | 385M | 540M | 783M | 783M | 700M | 588M | 749M | 1.19B | 1.56B | 1.79B |
| Total Liabilities | 42.7M | 49.2M | 61.1M | 84.0M | 156M | 159M | 187M | 317M | 455M | 337M | 407M |
| Shareholders' Equity | 518M | 335M | 479M | 699M | 627M | 541M | 400M | 432M | 733M | 1.23B | 1.39B |
| Cash & Short-term Investments | 529M | 341M | 474M | 697M | 632M | 521M | 417M | 439M | 756M | 820M | 976M |
| Total Debt | - | - | - | 9.80M | 49.5M | 64.4M | 62.0M | 57.2M | 52.0M | 52.2M | 71.9M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -210M | -218M | -167M | -151M | -136M | -126M | -114M | 16.7M | 158M | 110M | 240M |
| Capital Expenditure | 9.51M | 812K | 2.15M | 1.13M | 7.59M | 1.12M | 0.00 | 40.1M | 523K | 4.69M | 22.3M |
| Free Cash Flow | -220M | -219M | -170M | -152M | -144M | -127M | -114M | -23.3M | 157M | 105M | 218M |
| Ratios | |||||||||||
| ROE | -52.4% | -86.3% | -51.2% | -33.7% | -44.9% | -31.0% | -53.9% | -14.2% | 30.9% | 31.9% | 8.5% |
| ROA | -48.4% | -75.3% | -45.4% | -30.0% | -36.0% | -24.0% | -36.7% | -8.2% | 19.1% | 25.0% | 6.6% |
| Net Profit Margin | -1,565.9% | -231.7% | -109.6% | -69.4% | -63.7% | -34.7% | -41.8% | -8.4% | 23.6% | 36.5% | 9.7% |
| Debt to Equity | - | - | - | 0.01x | 0.08x | 0.12x | 0.15x | 0.13x | 0.07x | 0.04x | 0.05x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
ACADIA Pharmaceuticals Inc dividends
ACADIA Pharmaceuticals Inc has not paid dividends in the last 9 fiscal years.
Who owns ACADIA Pharmaceuticals Inc
- Insiders 0.33%
- Institutions 98.78%
- Public & others 0.89%
- Shares outstanding 173M
- Free float 129M
Top funds holding ACAD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| iShares Core S&P Small-Cap ETF | 7.77M | 4.50% | -0.10% | Oct 2026 |
| Vanguard MStar Total Stk Mkt Idx Invest | 4.10M | 2.37% | +0.37% | Sep 2026 |
| iShares Russell 2000 ETF | 3.26M | 1.89% | 0.00% | Oct 2026 |
| Vanguard Small Cap Index | 2.91M | 1.68% | -1.63% | Sep 2026 |
| State Street® SPDR® S&P® Biotech ETF | 2.65M | 1.54% | +2.69% | Oct 2026 |
| Vanguard MStar Small Cap Growth Indx Inv | 1.62M | 0.94% | -4.67% | Sep 2026 |
| Fidelity Small Cap Index | 1.41M | 0.82% | +0.16% | Aug 2026 |
| iShares Biotechnology ETF | 1.33M | 0.77% | -0.19% | Oct 2026 |
| iShares Russell 2000 Growth ETF | 1.21M | 0.70% | -0.38% | Oct 2026 |
| State Street SPDR Port S&P 600 Sm CpETF | 1.18M | 0.68% | -0.05% | Oct 2026 |
| iShares S&P Small-Cap 600 Growth ETF | 1.16M | 0.67% | -0.31% | Oct 2026 |
| Pictet-Biotech P USD | 931K | 0.54% | -16.27% | Jul 2026 |
| Vanguard Strategic Equity Inv | 908K | 0.53% | +29.70% | Sep 2026 |
| Vanguard Tax-Managed Small Cap Adm | 812K | 0.47% | 0.00% | Sep 2026 |
| Vanguard Russell 2000 ETF | 749K | 0.43% | +1.12% | Sep 2026 |
| State Street® SPDR® S&P 600™ Sm Cp GrETF | 732K | 0.42% | 0.00% | Oct 2026 |
| GS Glb Sm Cp CORE Eq Base Inc USD Snap | 719K | 0.42% | +286.52% | Aug 2026 |
| Schwab US Small-Cap ETF™ | 688K | 0.40% | +0.24% | Oct 2026 |
| Vanguard Explorer Inv | 663K | 0.38% | +26.54% | Sep 2026 |
| DFA U.S. Small Cap I | 642K | 0.37% | +0.61% | Sep 2026 |
Top institutions holding ACAD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Baker Bros Advisors LP | 42.9M | 24.83% | +0.04% | Jun 2026 |
| BlackRock Inc | 22.5M | 13.03% | +4.47% | Jun 2026 |
| State Street Corp | 9.08M | 5.25% | +8.92% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 8.84M | 5.11% | +1.92% | Jun 2026 |
| RTW INVESTMENTS, LLC | 7.14M | 4.13% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 5.76M | 3.33% | +1.81% | Jun 2026 |
| Dimensional Fund Advisors, Inc. | 3.37M | 1.95% | -8.90% | Sep 2026 |
| Geode Capital Management, LLC | 3.36M | 1.94% | -3.08% | Jun 2026 |
| Palo Alto Investors, LLC | 2.86M | 1.66% | -0.30% | Jun 2026 |
| The Goldman Sachs Group Inc | 2.58M | 1.49% | +65.63% | Jun 2026 |
| Qube Research & Technologies | 2.45M | 1.42% | +157.46% | Jun 2026 |
| Point72 Asset Management, L.P. | 2.43M | 1.41% | -5.61% | Jun 2026 |
| Citadel Advisors Llc | 2.18M | 1.26% | +250.40% | Jun 2026 |
| Pictet Asset Manangement SA | 1.98M | 1.15% | -2.11% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 1.97M | 1.14% | +25.48% | Jun 2026 |
| Marshall Wace Asset Management Ltd | 1.76M | 1.02% | +2,216.46% | Jun 2026 |
| D. E. Shaw & Co LP | 1.70M | 0.98% | +132.65% | Jun 2026 |
| BRAIDWELL LP | 1.65M | 0.95% | -33.38% | Jun 2026 |
| NORGES BANK | 1.62M | 0.94% | +7.68% | Jun 2026 |
| Frazier Life Sciences Management, L.P. | 1.44M | 0.83% | 0.00% | Jun 2026 |
ACADIA Pharmaceuticals Inc company profile
- Company name
- ACADIA Pharmaceuticals Inc
- Ticker
- ACAD.US
- Exchange
- USA Stocks
- Listed since
- May 27, 2004
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 796
- Fiscal year end
- December
- Address
- 12830 El Camino Real, San Diego, CA, United States, 92130
- Phone
- 858 558 2871
- Website
- acadia.com
About ACADIA Pharmaceuticals Inc
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.
ACADIA Pharmaceuticals Inc management
10- Ms. Catherine E. Owen AdamsCEO & Director · born 1970
- Mr. Mark C. SchneyerExecutive VP & CFO · born 1974
- Ms. Jennifer J. Rhodes J.D.Executive VP, Chief Legal Officer & Secretary · born 1970
- Mr. Thomas Andrew GarnerExecutive VP & Chief Commercial Officer · born 1976
- Mr. Scott CenciSenior VP, Chief Information & Data Officer
- Mr. Albert S. KildaniSenior Vice President of Investor Relations & Corporate Communications
- Mr. Carl SegerstromChief People Officer
- Mr. James K. KiharaSenior Vice President of Finance · born 1981
- Ms. Allyson McMillan-YoungbloodSenior Vice President of Rare Disease Franchise
- Ms. Konstantina KatchevesSenior VP, Chief Business & Strategy Officer